Lexicon Pharmaceuticals Stock Z Score

LXRX Stock

USD 0.79 0.01 0.76%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Lexicon Pharmaceuticals Piotroski F Score and Lexicon Pharmaceuticals Valuation analysis.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

At this time, Lexicon Pharmaceuticals' Change In Working Capital is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 145.7 M in 2024, whereas Capital Surpluse is likely to drop slightly above 1.5 B in 2024. At this time, Lexicon Pharmaceuticals' Interest Expense is fairly stable compared to the past year. Research Development is likely to rise to about 97.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 526.3 K in 2024.

Lexicon Pharmaceuticals Company Z Score Analysis

Lexicon Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Lexicon Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Lexicon Pharmaceuticals is extremely important. It helps to project a fair market value of Lexicon Stock properly, considering its historical fundamentals such as Z Score. Since Lexicon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexicon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexicon Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Good Will	Intangible Assets	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.39	0.51	-0.57	-0.11	0.47	0.18	0.88	0.78	0.98	0.33	0.53	0.35	0.32	0.43	0.75	0.1	0.1	-0.19	-0.16	0.62	-0.16	0.55	0.53	-0.4
Total Stockholder Equity	0.39		0.12	-0.55	0.31	0.18	-0.35	0.35	0.1	0.4	0.45	-0.12	-0.29	0.18	-0.09	0.34	0.43	0.54	-0.38	-0.25	0.34	0.31	0.3	0.25	-0.1
Current Deferred Revenue	0.51	0.12		-0.29	-0.43	0.59	0.09	0.64	0.57	0.61	-0.08	0.35	0.28	-0.25	0.37	0.09	-0.41	-0.13	0.31	0.45	0.72	-0.51	-0.05	-0.02	0.14
Net Debt	-0.57	-0.55	-0.29		-0.33	-0.17	0.48	-0.37	-0.15	-0.53	-0.34	-0.16	0.4	-0.42	-0.1	-0.58	-0.09	-0.55	0.63	0.41	-0.58	-0.22	-0.26	-0.14	0.42
Retained Earnings	-0.11	0.31	-0.43	-0.33		-0.26	-0.06	-0.16	-0.23	-0.13	0.34	-0.75	-0.43	0.52	-0.76	-0.02	0.51	0.6	-0.84	-0.85	0.03	0.58	0.56	0.48	-0.61
Accounts Payable	0.47	0.18	0.59	-0.17	-0.26		0.04	0.65	0.73	0.47	0.24	0.25	0.51	0.0	0.24	0.44	-0.07	-0.48	0.14	0.12	0.23	-0.1	0.24	0.21	-0.19
Net Receivables	0.18	-0.35	0.09	0.48	-0.06	0.04		0.3	0.36	0.23	0.13	0.04	0.56	-0.02	0.03	-0.24	-0.17	-0.2	0.2	0.01	-0.11	-0.11	0.47	0.58	-0.22
Short Term Investments	0.88	0.35	0.64	-0.37	-0.16	0.65	0.3		0.82	0.9	0.18	0.38	0.42	0.17	0.36	0.56	0.1	0.0	-0.09	0.02	0.6	-0.14	0.57	0.59	-0.25
Total Liab	0.78	0.1	0.57	-0.15	-0.23	0.73	0.36	0.82		0.79	0.17	0.35	0.79	0.11	0.31	0.55	0.01	-0.42	0.14	0.02	0.47	-0.44	0.5	0.49	-0.37
Total Current Assets	0.98	0.4	0.61	-0.53	-0.13	0.47	0.23	0.9	0.79		0.34	0.47	0.38	0.16	0.39	0.61	0.02	0.13	-0.1	-0.05	0.67	-0.23	0.52	0.51	-0.34
Short Term Debt	0.33	0.45	-0.08	-0.34	0.34	0.24	0.13	0.18	0.17	0.34		-0.04	0.01	0.18	-0.08	0.22	0.15	0.3	-0.35	-0.38	-0.14	0.5	0.47	0.44	-0.44
Common Stock	0.53	-0.12	0.35	-0.16	-0.75	0.25	0.04	0.38	0.35	0.47	-0.04		0.3	0.04	0.92	0.52	-0.35	-0.32	0.34	0.39	0.08	-0.28	-0.17	-0.14	0.16
Long Term Debt	0.35	-0.29	0.28	0.4	-0.43	0.51	0.56	0.42	0.79	0.38	0.01	0.3		-0.2	0.3	0.15	-0.2	-0.73	0.55	0.28	-0.02	-0.56	0.21	0.25	-0.14
Property Plant Equipment	0.32	0.18	-0.25	-0.42	0.52	0.0	-0.02	0.17	0.11	0.16	0.18	0.04	-0.2		-0.01	0.57	0.53	0.22	-0.74	-0.76	0.08	0.41	0.6	0.53	-0.56
Good Will	0.43	-0.09	0.37	-0.1	-0.76	0.24	0.03	0.36	0.31	0.39	-0.08	0.92	0.3	-0.01		0.38	-0.31	-0.32	0.36	0.54	0.04	-0.28	-0.18	-0.13	0.34
Intangible Assets	0.75	0.34	0.09	-0.58	-0.02	0.44	-0.24	0.56	0.55	0.61	0.22	0.52	0.15	0.57	0.38		0.28	-0.07	-0.38	-0.38	0.33	0.06	0.4	0.3	-0.47
Treasury Stock	0.1	0.43	-0.41	-0.09	0.51	-0.07	-0.17	0.1	0.01	0.02	0.15	-0.35	-0.2	0.53	-0.31	0.28		0.29	-0.52	-0.48	-0.02	0.4	0.5	0.48	-0.12
Net Tangible Assets	0.1	0.54	-0.13	-0.55	0.6	-0.48	-0.2	0.0	-0.42	0.13	0.3	-0.32	-0.73	0.22	-0.32	-0.07	0.29		-0.64	-0.41	0.27	0.51	0.25	0.23	-0.12
Long Term Debt Total	-0.19	-0.38	0.31	0.63	-0.84	0.14	0.2	-0.09	0.14	-0.1	-0.35	0.34	0.55	-0.74	0.36	-0.38	-0.52	-0.64		0.84	-0.16	-0.68	-0.62	-0.52	0.61
Capital Surpluse	-0.16	-0.25	0.45	0.41	-0.85	0.12	0.01	0.02	0.02	-0.05	-0.38	0.39	0.28	-0.76	0.54	-0.38	-0.48	-0.41	0.84		-0.03	-0.54	-0.65	-0.54	0.84
Deferred Long Term Liab	0.62	0.34	0.72	-0.58	0.03	0.23	-0.11	0.6	0.47	0.67	-0.14	0.08	-0.02	0.08	0.04	0.33	-0.02	0.27	-0.16	-0.03		-0.44	0.18	0.15	-0.14
Short Long Term Debt	-0.16	0.31	-0.51	-0.22	0.58	-0.1	-0.11	-0.14	-0.44	-0.23	0.5	-0.28	-0.56	0.41	-0.28	0.06	0.4	0.51	-0.68	-0.54	-0.44		0.38	0.34	-0.26
Net Invested Capital	0.55	0.3	-0.05	-0.26	0.56	0.24	0.47	0.57	0.5	0.52	0.47	-0.17	0.21	0.6	-0.18	0.4	0.5	0.25	-0.62	-0.65	0.18	0.38		0.98	-0.69
Net Working Capital	0.53	0.25	-0.02	-0.14	0.48	0.21	0.58	0.59	0.49	0.51	0.44	-0.14	0.25	0.53	-0.13	0.3	0.48	0.23	-0.52	-0.54	0.15	0.34	0.98		-0.58
Capital Stock	-0.4	-0.1	0.14	0.42	-0.61	-0.19	-0.22	-0.25	-0.37	-0.34	-0.44	0.16	-0.14	-0.56	0.34	-0.47	-0.12	-0.12	0.61	0.84	-0.14	-0.26	-0.69	-0.58

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Lexicon Pharmaceuticals

Based on the company's disclosures, Lexicon Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Lexicon Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Lexicon Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lexicon Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lexicon Pharmaceuticals' value.

		Shares
Pinnacle Associates Inc	2024-09-30	1.7 M
Charles Schwab Investment Management Inc	2024-09-30	1.4 M
Point72 Asset Management, L.p.	2024-09-30	1.2 M
Marshall Wace Asset Management Ltd	2024-06-30	1.2 M
Northern Trust Corp	2024-09-30	1.1 M
Braidwell Lp	2024-09-30	801.6 K
Wellington Management Company Llp	2024-06-30	738.6 K
Hennion & Walsh Asset Management Inc	2024-09-30	731.1 K
Morgan Stanley - Brokerage Accounts	2024-06-30	708.1 K
Artal Group S A	2024-06-30	175.1 M
Fmr Inc	2024-09-30	49.9 M

Lexicon Fundamentals

	Return On Equity	-1.36
	Return On Asset	-0.44
	Operating Margin	(36.40) %
	Current Valuation	133.79 M
	Shares Outstanding	361.49 M
	Shares Owned By Insiders	1.15 %
	Shares Owned By Institutions	82.02 %
	Number Of Shares Shorted	31.38 M
	Price To Earning	21.02 X
	Price To Book	1.63 X
	Price To Sales	55.64 X
	Revenue	1.2 M
	Gross Profit	(52.68 M)
	EBITDA	(163.46 M)
	Net Income	(177.12 M)
	Cash And Equivalents	61.97 M
	Cash Per Share	0.34 X
	Total Debt	106.06 M
	Debt To Equity	0.36 %
	Current Ratio	3.85 X
	Book Value Per Share	0.49 X
	Cash Flow From Operations	(161.9 M)
	Short Ratio	7.49 X
	Earnings Per Share	(0.74) X
	Price To Earnings To Growth	(0.14) X
	Target Price	4.2
	Number Of Employees	285
	Beta	1.24
	Market Capitalization	290.96 M
	Total Asset	229.43 M
	Retained Earnings	(1.77 B)
	Working Capital	145 M
	Current Asset	171.5 M
	Current Liabilities	31.77 M
	Net Asset	229.43 M

About Lexicon Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lexicon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lexicon Pharmaceuticals Stock Z Score

Lexicon Pharmaceuticals Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Lexicon Z Score Driver Correlations

Lexicon Pharmaceuticals Institutional Holders

Lexicon Fundamentals

About Lexicon Pharmaceuticals Fundamental Analysis

Also Currently Popular

Additional Tools for Lexicon Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY